Beijing CoSci-REMD Bio Med-Tech

Beijing CoSci-REMD Bio Med-Tech is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutic antibodies targeting G protein-coupled receptors (GPCRs). The company is a strategic entity associated with REMD Biotherapeutics, leveraging a proprietary platform to address metabolic diseases and oncology. Its lead candidate, Volagidemab (REMD-476), is a fully human monoclonal antibody targeting the glucagon receptor for the treatment of Type 1 and Type 2 diabetes. Additionally, the company is advancing a pipeline of candidates for indications such as NASH and various solid tumors. Beijing CoSci-REMD Bio Med-Tech operates R&D facilities in Beijing, integrating global innovation with local development capabilities.